- Home
- NFGC vs KURA Comparison
NFGC vs KURA Comparison
Compare NFGC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NFGC | KURA |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Canada | United States |
| Employees | N/A | 260 |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.8M | 765.8M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NFGC | KURA |
|---|---|---|
| Price | $2.03 | $8.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $25.88 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $3,542.00 | $25.83 |
| Revenue Next Year | $118.57 | $103.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $1.07 | $5.45 |
| 52 Week High | $3.59 | $12.49 |
Technical Indicators
Market Signals| Indicator | NFGC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 52.83 |
| Support Level | $1.84 | $8.09 |
| Resistance Level | $2.14 | $10.50 |
| Average True Range (ATR) | 0.13 | 0.43 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 79.12 | 72.20 |
Price Performance
Historical ComparisonAbout NFGC New Found Gold Corp
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.